Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes
NCT ID: NCT04184609
Last Updated: 2023-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2023-07-01
2023-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Physiotherapy on Dysfunctional Breathing in Children and Adolescents With and Without Asthma
NCT04728191
Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus
NCT04874610
Environmental Exposures, Genetics, and Exhaled Nitric Oxide in Pediatric Asthma
NCT00395096
Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma
NCT00279136
Inspiratory Pulmonary Rehabilitation for Children With Obesity and Asthma
NCT05608668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The overall objective of this study is to better understand the respiratory mechanisms provoking DOE in obese asthmatic children. The investigators hypothesize that low lung volume breathing in obesity leads to mechanical ventilatory constraints in the presence or absence of bronchoconstriction during exercise. Whereas DOE attributable to bronchoconstriction should respond to bronchodilators, DOE attributable to obesity-specific mechanical ventilatory constraints will not respond to bronchodilators. A comprehensive physiological pulmonary function and exercise-testing based approach will be used to identify 9-17-year-old obese asthmatic children who do and do not bronchoconstrict during exercise. The presence/absence of bronchoconstriction will be determined by a comprehensive measure of exercise-induced central and peripheral airway reactivity using spirometry and impulse oscillometry (i.e., greater than or equal to 10% reduction in forced expiratory volume in 1s, FEV1, or greater than or equal to 40% increase in peripheral airway resistance, R5-20, will be indicative of bronchoconstriction). The investigators will also determine the mechanisms by which bronchodilators like albuterol affect bronchoconstriction amd mechanical ventilatory constraints in asthmatic children with obesity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise test
All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design:
1. Control
2. Albuterol
Control
In this condition, the participants will not receive any medications or drugs before exercise
Albuterol
180 mcg of Albuterol will be administered before exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Control
In this condition, the participants will not receive any medications or drugs before exercise
Albuterol
180 mcg of Albuterol will be administered before exercise
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with physician diagnosed asthma will be recruited for this study.
* Objectively Confirmed Asthma Diagnosis: Asthma diagnosis will be confirmed objectively using spirometry (FEV1 \< 80% predicted or FEV1/FVC \< lower limit of normal), bronchodilator reversibility testing (post-bronchodilator improvement of ≥ 12% and 200mL in FEV1 or FVC; or a decrease in lung hyperinflation of at least 150 mL; ATS guidelines on lung function test interpretation). Patients in whom asthma cannot be confirmed objectively will be excluded from the study.
* Experience dyspnea on exertion as assessed by answering "yes" to one of the following two questions on the screening questionnaire: 1) Do you get short of breath with exertion? 2) Do you feel that your asthma is limiting you from participating in exercise?
* Ability to communicate in English
Body mass index criteria (BMI): We will study asthmatic children with obesity based on their BMI percentile:
• Obese: BMI ≥95th percentile and less than 170% of the 95th BMI percentile based on norms from the CDC
Exclusion Criteria
* Severe asthma: Forced expiratory volume in 1s (FEV1) \< 50% predicted
* Restrictive pulmonary disease: Forced vital capacity (FVC) and total lung capacity (TLC) \< 80% predicted
* Diffusion limitation: Diffusing capacity relative to alveolar volume (DLCO/VA) \< 80% predicted
Daily activity levels: Children participating in regular vigorous conditioning exercise such as running, jogging, aerobics, cycling, or swimming for ≥60min/session and ≥five times per week will be excluded to ensure similarity in physical activity levels between subjects and to avoid enrolling a potential high-fit, extremely active child. Children who participate in daily, unorganized physical activity (i.e., majority of children), will not be excluded. Children who are sedentary or only participate in school physical education classes will not be excluded.
* History of oral steroid medications for 4 weeks prior to enrollment
* History of being admitted to an intensive care unit or being intubated because of their asthma in the past five years
* History of allergy or hypersensitivity to albuterol
* On long acting muscarinic antagonists (LAMA)
* History of vocal cord dysfunction
* History of obesity hypoventilation syndrome
* History of untreated sleep apnea
* History of heart disease, metabolic disease, or renal disease that, in the opinion of the PI (or co-I's), would increase the risks of exercise testing or alter the physiological responses to exercise
* History of significant mental illness that in the opinion of the PI (or co-I's) would interfere with study participation or increase risks to the participant
* History of musculoskeletal abnormality that would preclude cycling exercise
* Pregnant or become pregnant during their participation in the study
* History of other significant illnesses that, in the opinion of the PI (or co-I's), either increase risks of participation or alter the physiological responses to exercise
* Inability to successfully complete pulmonary function or exercise testing measurements or difficulty with following instructions during testing
* Inability to tolerate testing procedures or complications related to testing
* If a participant develops hypoxemia or meets indications for terminating exercise, the exercise test will be terminated, and the participant will be referred for further evaluation In general, all participants will be encouraged to follow up with their asthma care provider or pediatrician for any health concerns that are discovered during their participation.
9 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nationwide Children's Hospital
OTHER
Ohio State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dharini Bhammar
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dharini M Bhammar, MBBS, PhD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ohio State University
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1481566
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.